Embed Size (px)
Citation preview
Fine
Schm
ecke
rs
IBR-Dormin® benefits for oily, acne prone skinOffice & Laboratory:4 Pekeris St., Tamar SciencePark, Rehovot 7670204, IsraelTel: +972-8-9465433Fax: [email protected]
Business Development& Marketing:Tel: +49-30-80589698Fax: [email protected]
DISCLAIMER: This catalog is designed to provide R&D and product development information on ingredients supplied by IBR as raw materials for cosmetic, food and other industries. This catalog is not designed to satisfy information requirements of consumers making use of the final product. The information contained herein is not applicable to, nor intended to satisfy, the legal/regulatory requirements of all countries. Nothing in this catalog is to be construed as the making of claims regarding the use of finished consumer products comprising IBR ingredients. Each manufacturer is responsible for ensuring that the claims made for and use of its products comply with the regulatory requirement of the countries in which it markets its products. Please be advised that you may display IBR trademarks, trade names, copyright, images and other IBR information only in promotional material and packaging for your products that contain IBR products purchased from IBR or an authorized IBR distributor and only if your products use IBR products in the concentration for which efficacy has been established. IBR’s products are protected by patents, patent applications, copyrights and trade secrets and nothing in this catalog gives you any rights under those patents, patent applications, copyrights or trade secrets. Your right to use IBR trademarks, trade names, copyright, images and other IBR information described in this paragraph is non-exclusive. In addition, upon your ceasing to use IBR products in your products, the right to use IBR trademarks, trade names, copyright, images and other information described in this paragraph shall immediately terminate and you will cease all such usage. © IBR. All Rights Reserved
INNOVATION INSPIRED BY NATURE
Patented technology by IBR Ltd.
Fine
Schm
ecke
rs
IBR-DORMIN®, SEBOCYTES, SEBUM AND ACNEIntroductionIBR-Dormin® (INCI: Narcissus Tazetta Bulb Extract) is a natural aqueous extract from Narcissus bulbs in their dormant stage that is able to slow cell proliferation in a reversible and general manner. Among cell types affected are also keratinocytes and sebocytes. IBR-Dormin® captures and transform flower bulbs dormancy and beauty to the skin.
Sebocytes and Sebum: sebum is an oily/waxy matter that is secreted by the sebaceous glands and produced by the specialized cells named sebocytes. The sebum is used to lubricate and water proof the skin and hair of mammals. In humans they are found in greater abundance in the face and scalp but also distributed throughout all skin sites. There are several medical conditions related to excess production of sebum that include seborrhea and acne.
Acne develops as a result of blockages in follicles or comedones as a result of enlargement and clogging of sebaceous glands and increased sebum production. Under these conditions, the naturally occurring bacteria, Propionibacterium acnes that nourish on the sebum and cell debris can cause inflammation expressed in lesions leading to scars and local pigmentation.
It’s been suggested that reduction in sebum production to reduce total oils in the skin may contribute to preventing and treating acne outbreaks.A way to control sebum production could therefore be reduction in sebocytes proliferation that leads to reduced production and secretion of sebum thereby reducing oiliness of the skin as suggest to be controlled by IBR-Dormin®.
in vitroBeing able to slowdown proliferation of cells in a non-specific manner, IBR- Dormin® was able to affect sebocytes proliferation while using primary sebocyte cultures.Using 0.05%-0.4% IBR-Dormin® for five days, a dose responsive reduction in sebocyte number, relative to untreated control, was observed, ranging from 48.9-89.3%, respectively.
CLINICAL STUDYEvaluation of the safety and efficacy of a gel product in the reduction of oiliness in a randomized, double blind, parallel treatment, placebo controlled trial.Test Product:
Gel Product with 1.5% IBR-Dormin - Code HGel Product with 1.5% IBR-Dormin + 0.5% Salicylic acid - Code FGel Product with 0.5% Salicylic acid - Code TCommercial Benchmark Cream (CBC) - Code M
Background: This was a double blind, single center study. There were four cells in the study with each cell using one test product.
Subjects: 80 subjects (20 for each product). Male or female, 13-20 years old and in general good health. Subjects had oily facial skin (Sebumeter reading of 180 and above). There were no adverse events reported during the study.
Procedure:The study lasted 8 weeks (2 weeks washout + 6 weeks treatment).
Instrumental assessment:Sebumeter Measurements
Expert assessment for:OilinessOpen comedonesBlackheads
Subject Self Assessment:Subject Self Assessment for parameters like oiliness, shine, dryness, flakiness and irritation.All assessments were taken at baseline, day 3, week 1, week 2, week 4 and week 6.Assessments were graded using a 1 to 10 scale (1= very unfavourable, 10= very favourable).
Open Comedones:Significant difference wrt baseline is observed in case of IBR-Dormin with sal acid (from week 1), CBC (from week 2) and IBR-Dormin alone (from week 4)Placebo shows no significant improvement wrt baseline.
Consumer Self AssessmentSubjects perceive significant improvement in oiliness vs baseline for all products except placebo from day 3 onwards.In case of placebo significant improvement is seen from week 1.Subjects also perceive improvement in shine for 1.5% IBR-Dormin from week 1. They also perceive that 1.5% IBR-Dormin and CBC formulation make their skin feel less dry from week 1.1.5% IBR-Dormin formulation is also perceived to reduce flaky patches on skin from week 4.Both CBC and placebo is perceived to improve softness from week 2.CBC is found to improve overall appearance from week 1, while 1.5% IBR- Dormin is found to improve overall appearance from week 2.
CONCLUSIONSIBR-Dormin® (INCI: Narcissus Tazetta Bulb Extract) ability to control and reduce cell proliferation of various types of cells including sebocytes may assist in reducing skin oiliness, shine, pore size and improves overall appearance. Together with ingredients that can control the acne related bacterial growth one may significantly affect acne outbreaks as well as post acne scaring and pigmentation.
RESULTSInstrumental AssessmentIBR-Dormin + sal acid shows significant reduction in sebumeter readings wrt baseline from day 3 until week 4.CBC shows significant difference wrt baseline from day 3 until week 2.Placebo shows significant difference only at day 3 and not at subsequent timepoints.
Dermatological Assessment
IBR-DORMIN® CONTROLS SEBUM, REDUCES SKIN OILINESS, SHINE AND PORE SIZE THEREBY BEAUTIFY THE SKIN AND ASSISTS CONTROLLING ACNE OUTBREAKS
Blackheads:Significant change is observed in case of IBR-Dormin + sal acid and CBC formulations from Week 1 onwards and this is maintained until week 6. IBR- Dormin without sal acid only formulation shows significant change from week 2 onwards.No significant change is observed in case of placebo wrt baseline. No significant difference observed between the products.
Oiliness:Significant decrease was observed in oiliness for both of the IBR- Dormin formulations and CBC from day 3 onwards until week 6. Placebo shows significant decrease from week 1.However no significant difference observed between the products.
Oiliness (% change vs. baseline)
IBR-Dormin®
Fine
Schm
ecke
rs
IBR-DORMIN®, SEBOCYTES, SEBUM AND ACNEIntroductionIBR-Dormin® (INCI: Narcissus Tazetta Bulb Extract) is a natural aqueous extract from Narcissus bulbs in their dormant stage that is able to slow cell proliferation in a reversible and general manner. Among cell types affected are also keratinocytes and sebocytes. IBR-Dormin® captures and transform flower bulbs dormancy and beauty to the skin.
Sebocytes and Sebum: sebum is an oily/waxy matter that is secreted by the sebaceous glands and produced by the specialized cells named sebocytes. The sebum is used to lubricate and water proof the skin and hair of mammals. In humans they are found in greater abundance in the face and scalp but also distributed throughout all skin sites. There are several medical conditions related to excess production of sebum that include seborrhea and acne.
Acne develops as a result of blockages in follicles or comedones as a result of enlargement and clogging of sebaceous glands and increased sebum production. Under these conditions, the naturally occurring bacteria, Propionibacterium acnes that nourish on the sebum and cell debris can cause inflammation expressed in lesions leading to scars and local pigmentation.
It’s been suggested that reduction in sebum production to reduce total oils in the skin may contribute to preventing and treating acne outbreaks.A way to control sebum production could therefore be reduction in sebocytes proliferation that leads to reduced production and secretion of sebum thereby reducing oiliness of the skin as suggest to be controlled by IBR-Dormin®.
in vitroBeing able to slowdown proliferation of cells in a non-specific manner, IBR- Dormin® was able to affect sebocytes proliferation while using primary sebocyte cultures.Using 0.05%-0.4% IBR-Dormin® for five days, a dose responsive reduction in sebocyte number, relative to untreated control, was observed, ranging from 48.9-89.3%, respectively.
CLINICAL STUDYEvaluation of the safety and efficacy of a gel product in the reduction of oiliness in a randomized, double blind, parallel treatment, placebo controlled trial.Test Product:
Gel Product with 1.5% IBR-Dormin - Code HGel Product with 1.5% IBR-Dormin + 0.5% Salicylic acid - Code FGel Product with 0.5% Salicylic acid - Code TCommercial Benchmark Cream (CBC) - Code M
Background: This was a double blind, single center study. There were four cells in the study with each cell using one test product.
Subjects: 80 subjects (20 for each product). Male or female, 13-20 years old and in general good health. Subjects had oily facial skin (Sebumeter reading of 180 and above). There were no adverse events reported during the study.
Procedure:The study lasted 8 weeks (2 weeks washout + 6 weeks treatment).
Instrumental assessment:Sebumeter Measurements
Expert assessment for:OilinessOpen comedonesBlackheads
Subject Self Assessment:Subject Self Assessment for parameters like oiliness, shine, dryness, flakiness and irritation.All assessments were taken at baseline, day 3, week 1, week 2, week 4 and week 6.Assessments were graded using a 1 to 10 scale (1= very unfavourable, 10= very favourable).
Open Comedones:Significant difference wrt baseline is observed in case of IBR-Dormin with sal acid (from week 1), CBC (from week 2) and IBR-Dormin alone (from week 4)Placebo shows no significant improvement wrt baseline.
Consumer Self AssessmentSubjects perceive significant improvement in oiliness vs baseline for all products except placebo from day 3 onwards.In case of placebo significant improvement is seen from week 1.Subjects also perceive improvement in shine for 1.5% IBR-Dormin from week 1. They also perceive that 1.5% IBR-Dormin and CBC formulation make their skin feel less dry from week 1.1.5% IBR-Dormin formulation is also perceived to reduce flaky patches on skin from week 4.Both CBC and placebo is perceived to improve softness from week 2.CBC is found to improve overall appearance from week 1, while 1.5% IBR- Dormin is found to improve overall appearance from week 2.
CONCLUSIONSIBR-Dormin® (INCI: Narcissus Tazetta Bulb Extract) ability to control and reduce cell proliferation of various types of cells including sebocytes may assist in reducing skin oiliness, shine, pore size and improves overall appearance. Together with ingredients that can control the acne related bacterial growth one may significantly affect acne outbreaks as well as post acne scaring and pigmentation.
RESULTSInstrumental AssessmentIBR-Dormin + sal acid shows significant reduction in sebumeter readings wrt baseline from day 3 until week 4.CBC shows significant difference wrt baseline from day 3 until week 2.Placebo shows significant difference only at day 3 and not at subsequent timepoints.
Dermatological Assessment
IBR-DORMIN® CONTROLS SEBUM, REDUCES SKIN OILINESS, SHINE AND PORE SIZE THEREBY BEAUTIFY THE SKIN AND ASSISTS CONTROLLING ACNE OUTBREAKS
Blackheads:Significant change is observed in case of IBR-Dormin + sal acid and CBC formulations from Week 1 onwards and this is maintained until week 6. IBR- Dormin without sal acid only formulation shows significant change from week 2 onwards.No significant change is observed in case of placebo wrt baseline. No significant difference observed between the products.
Oiliness:Significant decrease was observed in oiliness for both of the IBR- Dormin formulations and CBC from day 3 onwards until week 6. Placebo shows significant decrease from week 1.However no significant difference observed between the products.
Oiliness (% change vs. baseline)
IBR-Dormin®
Fine
Schm
ecke
rs
IBR-Dormin® benefits for oily, acne prone skinOffice & Laboratory:4 Pekeris St., Tamar SciencePark, Rehovot 7670204, IsraelTel: +972-8-9465433Fax: [email protected]
Business Development& Marketing:Tel: +49-30-80589698Fax: [email protected]
DISCLAIMER: This catalog is designed to provide R&D and product development information on ingredients supplied by IBR as raw materials for cosmetic, food and other industries. This catalog is not designed to satisfy information requirements of consumers making use of the final product. The information contained herein is not applicable to, nor intended to satisfy, the legal/regulatory requirements of all countries. Nothing in this catalog is to be construed as the making of claims regarding the use of finished consumer products comprising IBR ingredients. Each manufacturer is responsible for ensuring that the claims made for and use of its products comply with the regulatory requirement of the countries in which it markets its products. Please be advised that you may display IBR trademarks, trade names, copyright, images and other IBR information only in promotional material and packaging for your products that contain IBR products purchased from IBR or an authorized IBR distributor and only if your products use IBR products in the concentration for which efficacy has been established. IBR’s products are protected by patents, patent applications, copyrights and trade secrets and nothing in this catalog gives you any rights under those patents, patent applications, copyrights or trade secrets. Your right to use IBR trademarks, trade names, copyright, images and other IBR information described in this paragraph is non-exclusive. In addition, upon your ceasing to use IBR products in your products, the right to use IBR trademarks, trade names, copyright, images and other information described in this paragraph shall immediately terminate and you will cease all such usage. © IBR. All Rights Reserved
INNOVATION INSPIRED BY NATURE
Patented technology by IBR Ltd.
